APGE Apogee Therapeutics
111
$45.33
$0.15
(0.33%)
| Watchers | 111 |
| 52-Wk Low | $14.19 |
| 52-Wk High | $72.29 |
| Market Cap | $1.68B |
| Volume | 132,890.00 |
| 52-Wk High | $72.29 |
| 52-Wk Low | $14.19 |
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's WhyZacks Investment Research • 2 months ago
Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...
Share to Feed
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to...
Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report) rose 6% during trading on Friday . The company traded as high as $71.75 and last traded at $70.50. Approximately 222,641 shares traded...
Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report) has been given a consensus recommendation of Buy by the seven ratings firms that are presently covering the firm...
SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated...
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE Free Report) in a report published on Tuesday morning, RTT News reports. The brokerage currently has a...
Apogee Therapeutics (NASDAQ:APGE Free Report) had its target price upped by Guggenheim from $44.00 to $91.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They...
SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...
Apogee Therapeutics (NASDAQ:APGE Free Report) had its target price hoisted by Jefferies Financial Group from $37.00 to $75.00 in a research note issued to investors on Wednesday, Benzinga...
Apogee Therapeutics, Inc. (NASDAQ:APGE Get Free Report) shares traded up 6.8% during mid-day trading on Wednesday after Jefferies Financial Group raised their price target on the stock from...